ArticleInfection2025
Streptococcus suis endocarditis: prognostic factors and antimicrobial resistance.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Meeting the future at the Munich conference ESCMID-Global 2026.Infection · 2026Article
- Penicillin-nonsusceptible Streptococcus suis infections in humans: clinical characteristics and antimicrobial synergy testing.BMC infectious diseases · 2026Article
- Cryptococcal Endocarditis in Humans-A Narrative Review.Pathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeStreptococcus suis is an important zoonotic pathogen worldwide. This study aims to identify prognostic factors associated with the development of infective endocarditis (IE) and mortality in patients with S. suis bacteremia.
methodsA retrospective cross-sectional study was conducted by reviewing the medical records of patients with culture-confirmed S. suis infection admitted to a tertiary care hospital in Thailand between 2021 and 2023.
resultsAmong 200 patients with S. suis bacteremia who underwent echocardiograms, 102 (51%) were diagnosed with IE. Between 2021 and 2023, resistance to penicillin in S. suis increased from 13.0 to 38.7%, while intermediate susceptibility to ceftriaxone rose from 2.2 to 13.3%. Patients with S. suis bacteremia were at higher risk of developing IE if the strains were penicillin-resistant (aPR: 7.94, 95% CI: 1.13-55.80) or if persistent bacteremia was present (aPR: 1.58, 95% CI: 1.27-1.96) in multivariable analysis. Other risk factors included illness duration of more than 14 days (aPR: 2.19, 95% CI: 1.66-2.89) and being under 60 years of age (aPR: 1.42, 95% CI: 1.09-1.83). All-cause in-hospital mortality for patients with S. suis IE was 28.4% (95% CI: 19.9-38.2), higher than that of patients without IE (15.3%, 95% CI: 8.8-24.0). Embolic stroke and acute kidney injury increased the risk of death 3.28-fold (95% CI: 1.82-5.91) and 2.87-fold (95% CI: 1.06-7.79), respectively, after adjusting for confounders.
conclusionS. suis is a common cause of IE, particularly among antimicrobial-resistant strains, leading to high morbidity and mortality. Echocardiography is recommended for patients with S. suis bacteremia, although managing drug-resistant infections remains challenging.
Indexed as
Identifiers
40053287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.